Mabpharm (HKSE:02181) Other Long Term Assets : HK$1.98 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Mabpharm Other Long Term Assets?

Mabpharm's other long-term assets for the quarter that ended in Dec. 2023 was HK$1.98 Mil.

Mabpharm's quarterly other long-term assets increased from Dec. 2022 (HK$3.14 Mil) to Jun. 2023 (HK$3.25 Mil) but then stayed the same from Jun. 2023 (HK$3.25 Mil) to Dec. 2023 (HK$1.98 Mil).

Mabpharm's annual other long-term assets declined from Dec. 2021 (HK$11.31 Mil) to Dec. 2022 (HK$3.14 Mil) and declined from Dec. 2022 (HK$3.14 Mil) to Dec. 2023 (HK$1.98 Mil).

Mabpharm Other Long Term Assets Historical Data

The historical data trend for Mabpharm's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabpharm Other Long Term Assets Chart

Mabpharm Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long Term Assets

Get a 7-Day Free Trial

57.25

40.57

11.31

3.14

1.98

Mabpharm Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Long Term Assets	Get a 7-Day Free Trial								11.31	9.24	3.14	3.25	1.98

Mabpharm Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Mabpharm (HKSE:02181) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300

Website

http://www.mabpharm.cn

Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).

Executives

Guo Jianjun	2307 Founder of a discretionary trust who can infl
Asia Mabtech Limited
Asia Pacific Immunotech Venture Limited
Guo Family (ptc) Limited
Fortune-healthy Investment Limited
Link Best Capital Limited
Cdh Fund V, L.p.
Cdh Mabtech Limited
Cdh V Holdings Company Limited
China Diamond Holdings Company Limited
China Diamond Holdings V Limited

Mabpharm (HKSE:02181) Headlines

No Headlines